@article{7b21092abdce4c859015f1976f51807f,
title = "Targeting the KRAS G12C mutation in patients with advanced solid tumors",
author = "Hong, \{David S.\}",
note = "Funding Information: Dr Hong has received research/grant funding from AbbVie, Adaptimmune, Amgen, AstraZeneca, Bayer, BMS, Daiichi Sankyo, Eisai, Fate Therapeutics, Genentech, Genmab, Ignyta, Infinity, Kite, Kyowa Kirin, Lilly, LOXO, Merck, Funding Information: Dr Hong has received research/grant funding from AbbVie, Adaptimmune, Amgen, AstraZeneca, Bayer, BMS, Daiichi Sankyo, Eisai, Fate Therapeutics, Genentech, Genmab, Ignyta, Infinity, Kite, Kyowa Kirin, Lilly, LOXO, Merck, MedImmune, Mirati, Mirna, Molecular Templates, Mologen, NCI-CTEP, Novartis, Pfizer, Seattle Genetics, and Takeda. He has received reimbursement for travel, accommodations, and expenses from LOXO, Mirna, ASCO, AACR, SITC, and Genmab. He has a consulting or advisory role for Alpha Insights, Axiom, Adaptimmune, Baxter, Bayer, Genentech, DHG, groupH, Guidepoint Global, Infinity, Janssen, Merrimack, Medscape, Numab, Pfizer, Seattle Genetics, Takeda, and Trieza Therapeutics. Dr Hong has other ownership interests in MolecularMatch (advisor) OncoResponse (founder), and Presagia (advisor).",
year = "2019",
month = nov,
language = "English (US)",
volume = "17",
pages = "612--614",
journal = "Clinical Advances in Hematology and Oncology",
issn = "1543-0790",
publisher = "Millennium Medical Publishing, Inc.",
number = "11",
}